A phase II proof-of-concept trial of XEN1101 in adults with focal seizures
Phase of Trial: Phase II
Latest Information Update: 08 May 2018
At a glance
- Drugs XEN 1101 (Primary)
- Indications Partial epilepsies
- Focus Proof of concept; Therapeutic Use
- 08 May 2018 According to a Xenon Pharmaceuticals media release, the company anticipates initiating this trial by the end of 2018.
- 14 Nov 2017 New trial record
- 07 Nov 2017 According to a Xenon Pharmaceuticals media release, this study is anticipated to begin in the third quarter of 2018.